Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Kalvista Pharmaceuticals Inc (KALV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 412,031
  • Shares Outstanding, K 17,247
  • Annual Sales, $ 8,390 K
  • Annual Income, $ -15,810 K
  • 60-Month Beta 2.32
  • Price/Sales 22.84
  • Price/Cash Flow N/A
  • Price/Book 3.91

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 04/30/19
See More
  • Average Estimate -0.45
  • Number of Estimates 3
  • High Estimate -0.26
  • Low Estimate -0.79
  • Prior Year -0.06
  • Growth Rate Est. (year over year) -650.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.50 +11.12%
on 05/06/19
25.55 -6.50%
on 05/15/19
-0.13 (-0.54%)
since 04/24/19
3-Month
20.76 +15.08%
on 02/25/19
34.92 -31.59%
on 03/14/19
+3.28 (+15.91%)
since 02/22/19
52-Week
7.73 +209.06%
on 06/18/18
34.92 -31.59%
on 03/14/19
+14.90 (+165.74%)
since 05/24/18

Most Recent Stories

More News
Rigel Initiates Enrollment in Pivotal Blood Disorder Study

Rigel (RIGL) enrolls first patient in a pivotal label expansion study evaluating its approved drug, Tavalisse, in patients with antibody autoimmune hemolytic anemia.

KALV : 23.89 (+1.06%)
AZN : 39.02 (+0.93%)
RIGL : 2.14 (+5.94%)
ACRS : 5.12 (+1.79%)
KalVista Pharmaceuticals (KALV) Upgraded to Strong Buy: Here's Why

KalVista Pharmaceuticals (KALV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

KALV : 23.89 (+1.06%)
KalVista Pharmaceuticals Presents Data at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2019

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced...

KALV : 23.89 (+1.06%)
KalVista Pharmaceuticals Appoints Daniel B. Soland to Board of Directors

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors,...

KALV : 23.89 (+1.06%)
Small Drugmakers Outperforming the Bigshots: 7 Stocks to Buy

Smaller drugmakers are having a relatively better 2019 than their larger counterparts. Here are seven stocks to buy.

KALV : 23.89 (+1.06%)
ACRX : 2.74 (-2.14%)
ALPN : 4.80 (-15.49%)
OTIC : 2.56 (-0.78%)
MTEM : 8.11 (+4.11%)
TCDA : 37.46 (-1.11%)
ATNM : 0.29 (+4.25%)
KalVista Pharmaceuticals to Present at Needham Healthcare Conference

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors,...

KALV : 23.89 (+1.06%)
Recent Analysis Shows Wells Fargo, Public Service Enterprise Group, Apartment Investment and Management, Gentherm, Connecticut Water Service, and KalVista Pharmaceuticals Market Influences -- Renewed Outlook, Key Drivers of Growth

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Wells Fargo & Company (NYSE:WFC),...

CTWS : 69.82 (+0.49%)
PEG : 61.16 (-0.36%)
KALV : 23.89 (+1.06%)
WFC : 46.17 (+1.34%)
THRM : 38.95 (+2.04%)
AIV : 51.04 (+0.10%)
KalVista Pharmaceuticals Announces the Promotion of Benjamin L. Palleiko to Include Chief Business Officer

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors,...

KALV : 23.89 (+1.06%)
What Makes KalVista Pharmaceuticals (KALV) a Strong Momentum Stock: Buy Now?

Does KalVista Pharmaceuticals (KALV) have what it takes to be a top stock pick for momentum investors? Let's find out.

KALV : 23.89 (+1.06%)
KalVista Pharmaceuticals Reports Fiscal Third Quarter Results

--- Intravitreal Diabetic Macular Edema (DME) Candidate KVD001 Phase 2 Trial Completion Expected H2 2019 -

KALV : 23.89 (+1.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More Share

Trade KALV with:

Business Summary

KalVista Pharmaceuticals, Inc. is a pharmaceuticals company. It engages in discovery, development and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product portfolio consist hereditary angioedema and diabetic macular edema, KVD818 and KVD001, which...

See More

Key Turning Points

2nd Resistance Point 24.62
1st Resistance Point 24.26
Last Price 23.89
1st Support Level 23.46
2nd Support Level 23.03

See More

52-Week High 34.92
Fibonacci 61.8% 24.53
Last Price 23.89
Fibonacci 50% 21.32
Fibonacci 38.2% 18.12
52-Week Low 7.73

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar